NitroMed Aims To Revive BiDil With CEO Change, Managed Care Push
Executive Summary
NitroMed's strategy for jump-starting sales of BiDil includes renewed efforts to get favorable formulary placement for the heart failure drug
You may also be interested in...
Nitromed Reverse Merger Is Quickest Way To Cash For Archemix
Nitromed’s status as essentially a publicly-traded cash shell, with the sell-off of BiDil, made it an attractive partner.
Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class
Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class